On Tuesday, Truist Securities began coverage on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), issuing a Buy rating and setting a price target of $25.00.The announcement from ...

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $25. Teva Pharma is an ...

As Teva Pharma prepares for its investor day, investors and market watchers will be closely monitoring the company’s disclosures and Truist’s analysis. In other recent news, Teva Pharmaceutical ...

On Friday, Goldman Sachs (NYSE: GS) analysts initiated coverage on Teva Pharmaceutical Industries Ltd. (NYSE: NYSE: TEVA) with a Buy rating and set a price target of $24.00.The analysts highlighted an ...

Teva’s plan (PDF) to reach $5 billion in 2030 innovative drug sales places the greatest emphasis on Austedo, which the company foresees hitting at least $2.5 billion in 2027 before reaching a ...

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its ...

While this would weigh heavily on standard generic pharma companies, it could present an opportunity for bigger copycat drugmakers, such as Teva and Amneal, to scoop up some of the competition ...

Teva Investor Relations Inquiries: TevaIR@Tevapharm.com The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties.

Prestige Biopharma announced on the 26th that it has signed a sales and supply agreement for the biosimilar 'Tuznue' (ingredient name trastuzumab) with Teva Pharmaceutical Industries' subsidiary ...